Gaviscon suspension 300ml peppermint fl

Description

Composition
Active substance:
Sodium alginate 500 mg, 267 mg sodium hydrogen carbonate, calcium carbonate 160 mg
Excipients:
carbomer 65 mg, 40 mg methyl parahydroxybenzoate, propyl parahydroxybenzoate 6 mg sodium saccharinate 10 mg, mint oil, peppermint 1 mg 26.667 mg of sodium hydroxide, purified water to 10 ml.
Description:
Viscous opaque slurry from nearly white to cream color with a mint odor.
Product form:
300 ml amber glass vials with a polypropylene cap, providing a first control opening. Instructions for use under the label.
Contraindications
Hypersensitivity to any component of the drug, children’s age (up to 6 years).
Indications
Symptomatic treatment of dyspepsia associated with gastric hyperacidity and gastroesophageal reflux (heartburn, acid regurgitation), a feeling of heaviness in the stomach after ingestion, including during pregnancy.
Interaction with other drugs
Since the calcium carbonate, part of the drug exhibits antacid activity between drug intake Geviskon® and other drugs must be at least 2 hours, particularly while receiving H2-blockers of histamine receptors, antibiotics from the group of tetracycline, digoxin, fluoroquinolone, iron salts, ketoconazole, neuroleptics, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propranolol), corticosteroids, chloroquine, bisphosphonates and estramustine.
Overdose
Symptoms may experience bloating.
Treatment: symptomatic.
pharmachologic effect
Pharmacological group:
Reflux esophagitis treatment for
Pharmacodynamics:
When ingestion of the active ingredients of the drug Geviskon® quickly react with acidic stomach contents. This forms an alginate gel with a pH close to neutral. The gel forms a protective barrier on the surface of the gastric contents, preventing the occurrence of gastroesophageal reflux (Scored reverse stomach contents into the esophagus) for up to four hours. In severe cases of reflux (regurgitation), the gel enters the esophagus, the stomach contents ahead of the rest, where it reduces irritation of esophageal mucosa.
Reducing irritation felt after 3-4 minutes after administration.
Pharmacokinetics:
The mechanism of drug action Geviskon® is a physical process, and hence, the therapeutic effect of the drug is carried out without absorption into the systemic circulation.
Pregnancy and breast-feeding
The drug can be used during pregnancy and lactation.
Conditions of supply of pharmacies
Without recipe.
side effects
estimates of frequency of adverse reactions produced on the basis of the following criteria: very common (> 1/10), common (> 1/100, 1/1000, 1/10000,
Disorders of immune system: unknown frequency – anaphylactic and anaphylactoid reactions, hypersensitivity reactions (urticaria).
Violations of the respiratory system, thorax and mediastinum: unknown frequency – respiratory effects (bronchospasm).
If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
In 10 ml of a suspension of sodium content of 141 mg (6.2 mmol). This should be considered if necessary to diet with very limited content of salt, for example, in some cases of congestive heart failure and renal impairment. If there is no improvement in symptoms within 7 days should consult a physician.
Effects on ability to transp. Wed. and fur .:
The drug has no effect on the ability to drive vehicles and mechanisms, as well as other classes of potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Store at a temperature of from 15 ° C to 25 ° C. Keep out of the reach of children.
Dosing and Administration
Adults and children over 12 years: inside of 10-20 ml after meals and at bedtime.
The maximum daily dose for adults and children over 12 years: 80 ml.
Children aged 6 to 12 years: inwards 5-10 ml after meals and at bedtime.
The maximum daily dose for children aged 6 to 12 years: 40 ml.
Do not use the drug for a long time, if after 7 days dosing symptoms persist, seek medical advice to revise the therapies.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist